BCL2 and neoplasm: Somatic mutations affecting the cytosolic domains of BCL2 correlate with poor prognosis and a loss of sensitivity to anti-tumor treatments, which has prompted the development of alternative therapeutic strategies for affected cancer patients [5, 12, 13].